GPCR/G protein
All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
- B4575 AL 8810Target: prostaglandin FP receptorSummary: Antagonist of prostaglandin F2α (FP) receptor.
- B5994 Cyclobenzaprine HClSummary: 5-HT2 receptor antagonist
- B6038 Ozanimod (RPC1063)Summary: agonist of the sphingosine-1-phosphate receptor subtypes 1 and 5
- B6111 Lu AF21934Summary: positive allosteric modulator of mGlu4 receptors
- B7809 PonesimodSummary: sphingosine-1-phosphate receptor 1 (S1P1) modulator
- B7814 ATI-2341Summary: CXCR4 allosteric agonist
- B7818 ONO-7300243Target: LPASummary: LPA1 antagonist
- B7833 BKT140Summary: CXCR4 antagonist
- C3019 Erythromycin A enol etherSummary: β-turn mimic of the peptide hormone motilin
- C3021 L-PhenylephrineSummary: adrenergic α1A receptor agonist